Halozyme (HALO) Rule 144: Affiliate sold 100,000 shares

Halozyme Therapeutics reported multiple Rule 144 sale notices for Common Stock by an affiliated seller.

Rhea-AI Filing Summary

Halozyme Therapeutics reported multiple Rule 144 sale notices for Common Stock by an affiliated seller. The filing lists sales of 20,000 shares on 03/02/2026, 20,000 on 03/03/2026, 10,000 on 03/04/2026, 20,000 on 04/01/2026, 20,000 on 04/02/2026, and 10,000 on 04/06/2026.

The filing also indicates a planned stock option exercise and sale dated 05/11/2026 involving Common Stock with cash settlement. The seller is identified as Helen Torley at Halozyme Therapeutics.

Insights

Securities Compliance Officer

Rule 144 notices document completed and planned affiliate dispositions.

The filing lists multiple small open-market or Rule 144 dispositions totaling 100,000 shares across March–April 2026 and an indicated stock option exercise/sale on 05/11/2026. These entries are procedural notices for an affiliated holder.

Cash‑flow treatment is the seller's proceeds; timing for the May exercise is stated as 05/11/2026. Subsequent SEC filings would show actual trade execution details and any required Form 4/5 reporting.

Key Figures

Total reported disposals (Mar–Apr 2026): 100,000 shares Single-lot sizes: 10,000–20,000 shares Planned option exercise date: 05/11/2026 +1 more

4 metrics

Total reported disposals (Mar–Apr 2026) 100,000 shares aggregate of six listed dispositions between 03/02/2026 and 04/06/2026

Single-lot sizes 10,000–20,000 shares individual reported dispositions on listed dates in Mar–Apr 2026

Planned option exercise date 05/11/2026 stock option exercise and sale entry dated in the filing

Settlement method for May exercise Cash stock option exercise listed with cash settlement on 05/11/2026

Key Terms

Rule 144, Stock Option Exercise, Settlement method: Cash

3 terms

Rule 144 regulatory

"lists multiple Rule 144 sale notices for Common Stock by an affiliated seller"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Stock Option Exercise on 05/11/2026 with settlement method Cash"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Settlement method: Cash financial

"Stock Option Exercise ... Cash"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Halozyme Therapeutics (HALO) disclose in this Rule 144 filing?

The filing discloses multiple affiliate share dispositions: 20,000 shares on 03/02/2026, 20,000 on 03/03/2026, and additional sales through 04/06/2026. It also notes a stock option exercise/sale dated 05/11/2026.

Who is the seller named in the HALO Rule 144 filing?

The seller is identified as Helen Torley at Halozyme Therapeutics with the address shown. She is listed as the affiliated holder reporting multiple share dispositions across March and April 2026.

How many shares were reported sold in the March–April 2026 entries?

The March–April entries list six dispositions totaling 100,000 shares: two 20,000 lots in March, one 10,000 lot in March, and three lots (20,000; 20,000; 10,000) in April 2026 as shown in the filing.

Does the filing state how the May 11, 2026 stock option exercise will be settled?

Yes. The filing lists a Stock Option Exercise on 05/11/2026 with settlement method shown as Cash, indicating exercise and cash payment terms for the referenced shares in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 04:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001528185
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Halozyme Therapeutics, Inc.
SEC File Number	001-32335
Address of Issuer	12390 El Camino Real San Diego CALIFORNIA 92130
Phone	858-794-8889
Name of Person for Whose Account the Securities are To Be Sold	Helen Torley
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	President, CEO, Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	101923	6535303	118017000	05/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/11/2026	Stock Option Exercise	Issuer			101923	05/11/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	03/02/2026	20000	1393889
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	03/03/2026	20000	1380153
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	03/04/2026	10000	702114
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	04/01/2026	20000	1307514
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	04/02/2026	20000	1284718
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	04/06/2026	10000	634982

144: Remarks and Signature

Remarks	The shares covered by this filing are stock options that will be exercised within three months from the date of this filing.
Date of Notice	05/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/21/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Helen Torley
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)